MacroGenics sells ZYNYZ royalty rights to Sagard for $70M; cash runway extended into H1 2027

MACROGENICS INC

Received $70M upfront from Sagard for capped royalty on global net sales of ZYNYZ (retifanlimab-dlwr).
After Sagard collects $140M in royalties (2.0x), MacroGenics resumes all future royalty payments.
MacroGenics retains other ZYNYZ economic interests, including development and commercial milestones.
Cash, equivalents and securities were $154.1M at March 31, 2025; combined with $70M, runway now through first half 2027.
ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte in 2017.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.